Company Analysis

Puma Biotechnology Inc (PBYI)

Nasdaq: PBYI · Pharmaceutical Preparations · Los Angeles, CA · filing with the SEC since 2007
Grade6.2
◀ Past 5.8● Present 7.6▶ Future 4.7

Who runs Puma Biotechnology Inc

Officers and directors as they report to the SEC on Forms 3, 4 and 5, named as filed
Chief executive, as filed
Auerbach Alan H
President and CEO. First filing Oct 2011, latest Jul 8, 2026, 63 filings in all.
Officers reporting now
3
of 10 people with a filing in the last fifteen months
Directors reporting now
7
20 people on the record since 2011
Officerssales are open-market, Sep 30, 2025 to Sep 30, 2026
NameTitle as filedFirst filingLatest filingSales, 12 months
Auerbach Alan HPresident and CEOOct 2011Jul 8, 20263 · $600,000
Hunt Douglas MThe Reporting Person is the Senior Vice President of Regulatory Affairs of the Issuer.Jan 2018Jul 8, 20263 · $100,000
Nougues Maximo FChief Financial OfficerNov 2018Jul 8, 20263 · $100,000
Directorssales are open-market, Sep 30, 2025 to Sep 30, 2026
NameRoleFirst filingLatest filingSales, 12 months
Cesano AlessandradirectorAug 2022Sep 16, 20261 · $600,000
Wilson Troy EdwarddirectorOct 2013Sep 16, 20262 · $100,000
Dorval AllisondirectorJul 2021Jun 15, 20261 · $100,000
Miller Michael PatrickdirectorFeb 2018Jun 15, 20261 · $100,000
Moyes Jay MdirectorApr 2012Jun 15, 20261 · $200,000
Senderowicz AdriandirectorAug 2015Jun 15, 20261 · $200,000
Stuglik Brian MdirectorJul 2020Jun 15, 20261 · $100,000
Earlier names on the record15, newest filing first

A person is listed as reporting now after a filing in the last fifteen months. The record shows when someone last filed; it does not say why they stopped. Each name links to the filings on sec.gov.

SI Assistanton PBYI · research, not advice